Literature DB >> 29975342

A Cost Reimbursement Model for Hepatitis C Treatment Care Coordination.

Czarina N Behrends1, Ashley A Eggman, Sarah Gutkind, Marie P Bresnahan, Kyle Fluegge, Fabienne Laraque, Alain H Litwin, Paul Meissner, Shuchin J Shukla, Ponni V Perumalswami, Jeffrey Weiss, Brooke E Wyatt, Bruce R Schackman.   

Abstract

OBJECTIVE: To estimate the cost of delivering a hepatitis C virus care coordination program at 2 New York City health care provider organizations and describe a potential payment model for these currently nonreimbursed services.
DESIGN: An economic evaluation of a hepatitis C care coordination program was conducted using micro-costing methods compared with macro-costing methods. A potential payment model was calculated for 3 phases: enrollment to treatment initiation, treatment initiation to treatment completion, and a bonus payment for laboratory evidence of successful treatment outcome (sustained viral response).
SETTING: Two New York City health care provider organizations. PARTICIPANTS: Care coordinators and peer educators delivering care coordination services were interviewed about time spent on service provision. De-identified individual-level data on study participant utilization of services were also used. INTERVENTION: Project INSPIRE is an innovative hepatitis C care coordination program developed by the New York City Department of Health and Mental Hygiene. MAIN OUTCOME MEASURES: Average cost per participant per episode of care for 2 provider organizations and a proposed payment model.
RESULTS: The average cost per participant at 1 provider organization was $787 ($522 nonoverhead cost, $264 overhead) per episode of care (5.6 months) and $656 ($429 nonoverhead cost, $227 overhead, 5.7 months) at the other one. The first organization had a lower macro-costing estimate ($561 vs $787) whereas the other one had a higher macro-costing estimate ($775 vs $656). In the 3-phased payment model, phase 1 reimbursement would vary between the provider organizations from approximately $280 to $400, but reimbursement for both organizations would be approximately $220 for phase 2 and approximately $185 for phase 3.
CONCLUSIONS: The cost of this 5.6-month care coordination intervention was less than $800 including overhead or less than $95 per month. A 3-phase payment model is proposed and requires further evaluation for implementation feasibility. Project INSPIRE's HCV care coordination program provides good value for a cost of less than $95 per participant per month. The payment model provides an incentive for successful cure of hepatitis C with a bonus payment; using the bonus payment to support HCV tele-mentoring expands HCV treatment capacity and empowers more primary care providers to treat their own patients with HCV.

Entities:  

Mesh:

Year:  2019        PMID: 29975342      PMCID: PMC6314903          DOI: 10.1097/PHH.0000000000000806

Source DB:  PubMed          Journal:  J Public Health Manag Pract        ISSN: 1078-4659


  18 in total

1.  Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.

Authors:  Lauren A Canary; R Monina Klevens; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2015-08-04       Impact factor: 25.391

2.  Medicare Payment for Behavioral Health Integration.

Authors:  Matthew J Press; Ryan Howe; Michael Schoenbaum; Sean Cavanaugh; Ann Marshall; Lindsey Baldwin; Patrick H Conway
Journal:  N Engl J Med       Date:  2016-12-14       Impact factor: 91.245

3.  Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States.

Authors:  Soumitri Barua; Robert Greenwald; Jason Grebely; Gregory J Dore; Tracy Swan; Lynn E Taylor
Journal:  Ann Intern Med       Date:  2015-08-04       Impact factor: 25.391

4.  Outcomes of HIV/AIDS case management in New York.

Authors:  S E Lehrman; D Gentry; B B Yurchak; J Freedman
Journal:  AIDS Care       Date:  2001-08

5.  Partnering urban academic medical centers and rural primary care clinicians to provide complex chronic disease care.

Authors:  Sanjeev Arora; Summers Kalishman; Denise Dion; Dara Som; Karla Thornton; Arthur Bankhurst; Jeanne Boyle; Michelle Harkins; Kathleen Moseley; Glen Murata; Miriam Komaramy; Joanna Katzman; Kathleen Colleran; Paulina Deming; Sean Yutzy
Journal:  Health Aff (Millwood)       Date:  2011-05-19       Impact factor: 6.301

6.  Effects of care coordination on hospitalization, quality of care, and health care expenditures among Medicare beneficiaries: 15 randomized trials.

Authors:  Deborah Peikes; Arnold Chen; Jennifer Schore; Randall Brown
Journal:  JAMA       Date:  2009-02-11       Impact factor: 56.272

Review 7.  Global estimates of prevalence of HCV infection among injecting drug users.

Authors:  Carmen Aceijas; Tim Rhodes
Journal:  Int J Drug Policy       Date:  2007-08-07

8.  Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States.

Authors:  Sammy Saab; Melissa Jimenez; Tiffany Fong; Crystal Wu; Sherona Bau; Zoha Jamal; Jonathan Grotts; David Elashoff
Journal:  J Clin Transl Hepatol       Date:  2016-06-15

9.  Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study.

Authors:  Karen M Clements; Robin E Clark; Pavel Lavitas; Parag Kunte; Camilla S Graham; Elizabeth O'Connell; Kimberly Lenz; Paul Jeffrey
Journal:  J Manag Care Spec Pharm       Date:  2016-06

10.  The Impact of Comprehensive Case Management on HIV Client Outcomes.

Authors:  Mark Brennan-Ing; Liz Seidel; Leslie Rodgers; Jerome Ernst; Doug Wirth; Daniel Tietz; Antonio Morretti; Stephen E Karpiak
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

View more
  5 in total

Review 1.  Closing the hepatitis C treatment gap: United States strategies to improve retention in care.

Authors:  Austin T Jones; Christopher Briones; Torrence Tran; Lisa Moreno-Walton; Patricia J Kissinger
Journal:  J Viral Hepat       Date:  2022-05-26       Impact factor: 3.517

2.  Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City.

Authors:  Czarina N Behrends; Sarah Gutkind; Regan Deming; Kyle R Fluegge; Marie P Bresnahan; Bruce R Schackman
Journal:  J Urban Health       Date:  2021-08       Impact factor: 5.801

3.  A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure.

Authors:  Brooke Wyatt; Ponni V Perumalswami; Anna Mageras; Mark Miller; Alyson Harty; Ning Ma; Chip A Bowman; Francina Collado; Jihae Jeon; Lismeiry Paulino; Amreen Dinani; Douglas Dieterich; Li Li; Maxence Vandromme; Andrea D Branch
Journal:  Hepatology       Date:  2021-12       Impact factor: 17.298

4.  Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs.

Authors:  Sarah Gutkind; Laura E Starbird; Sean M Murphy; Paul A Teixeira; Lauren K Gooden; Tim Matheson; Daniel J Feaster; Mamta K Jain; Carmen L Masson; David C Perlman; Carlos Del Rio; Lisa R Metsch; Bruce R Schackman
Journal:  Drug Alcohol Depend       Date:  2022-01-10       Impact factor: 4.852

Review 5.  Innovations in Hepatitis C Screening and Treatment.

Authors:  Arpan A Patel; Aileen Bui; Eian Prohl; Debika Bhattacharya; Su Wang; Andrea D Branch; Ponni V Perumalswami
Journal:  Hepatol Commun       Date:  2020-12-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.